



COPY OF PAPERS
ORIGINALLY FILED

1635 #6
5-7-02

PATENT APPLICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

4/19/02

Date

Gary E. Parker

Gary E. Parker

TECH CENTER 1600/2900

MAY 02 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Debra G. Gilbertson
Serial No. : 09/695,121
Filed : October 23, 2000
For : METHOD FOR TREATING FIBROSIS
Examiner : Angell, Jon E.
Art Unit : 1635
Docket No. : 00-53
Date : April 19, 2002

Commissioner for Patents
Washington, D.C. 20231

Response to Restriction Requirement and Amendment

Sir:

In response to the Office Action dated March 21, 2002, please amend the above-identified patent application as follows:

In the Claims:

Please replace claims 1, 9, 11, 15, and 17 with the following amended claims:

1. (amended) A method of reducing cell proliferation or extracellular matrix production in a mammal comprising administering to the mammal a composition comprising a zveg3 antagonist in combination with a pharmaceutically acceptable delivery vehicle, in an amount sufficient to reduce cell proliferation or extracellular matrix production, wherein said zveg3 antagonist is an antibody that specifically binds to a dimeric protein having two polypeptide chains, wherein each of said polypeptide chains consists of a sequence of amino acid residues selected from the group consisting of:

A'